Repositioning compounds for idiopathic pulmonary fibrosis treatment: seeking the future in the past
- PMID: 38754951
- DOI: 10.1183/13993003.00678-2024
Repositioning compounds for idiopathic pulmonary fibrosis treatment: seeking the future in the past
Conflict of interest statement
Conflict of interest: B. Crestani reports grants from Boehringer Ingelheim, consultancy fees from BMS, Boehringer Ingelheim, Chiesi, CSL Behring, GSK and Sanofi, payment or honoraria for lectures, presentations, manuscript writing or educational events from AstraZeneca, BMS, Boehringer Ingelheim, GSK, Novartis, Roche and Sanofi, support for attending meetings from AstraZeneca, BMS, Boehringer Ingelheim, Roche and Sanofi, participation on a data safety monitoring board or advisory board with BMS, Boehringer Ingelheim, Horizon and Sanofi, and is president of the board of trustees of the Fondation du Souffle.
Comment on
-
Repositioning of ezetimibe for the treatment of idiopathic pulmonary fibrosis.Eur Respir J. 2024 May 16;63(5):2300580. doi: 10.1183/13993003.00580-2023. Print 2024 May. Eur Respir J. 2024. PMID: 38359963 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources